Low and intermediate risk prostate cancer, defined as clinical stage T1-2b, Gleason Score less than/equal to 7, and PSA less than 20 ng/mL (low risk patients will have refused or felt to be inappropriate for active surveillance)
You may not be if
Androgen deprivation therapy (LHRH-agonists or antiandrogens)\>6 mo
Prior pelvic radiotherapy
Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
Diagnosis of bleeding diathesis
Large prostate (\>90cm3) on imaging
Immunosuppressive medications
Inflammatory bowel disease
Presence of a hip prosthesis
Clareo Health | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer
